Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biotechs Spar Over Algae
by Marc S. Reisch
March 9, 2015
| A version of this story appeared in
Volume 93, Issue 10
Solazyme has asked a U.S. federal court to uphold an arbitration award of $2.3 million and intellectual property developed with former partner Roquette. The two had a joint venture, starting in 2010 but dissolved in 2013, to research and market microalgae-derived ingredients for human and animal consumption. Solazyme says the venture got under way with its intellectual property, which Roquette promised not to reverse-engineer but did. In addition to the arbitration award, Solzyme is asking the court for punitive damages and an order barring Roquette from using its intellectual property.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter